ClinicalTrials.gg
CompletedNCT01153971Updated Aug 1, 2017Results posted

A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas

A Phase 2 interventional study of rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 15 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-08-01.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 10 months after the study started (first participant enrolled Jul 2005, registered Jun 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
74th of 171
47 · median 38
Started
2005
with 10 others
Phase 2
94 of 178
3 open now
Registered
116th of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 74th largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2005, is one of 94 in phase 2, and was the 116th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is \<100 individuals.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients 18-65 years of age;
  • previously untreated indolent nonfollicular non-Hodgkin's lymphoma;
  • active disease;
  • >=3 involved sites.

Exclusion criteria

Exclusion Criteria:

  • typical chronic lymphocytic leukemia;
  • other within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix;
  • systemic use for >1 month;
  • significant cardiovascular disease;
  • central nervous system involvement;
  • or C virus infection, or infection.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    1

    Drug: rituximab

Interventions

  • 1

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date

    Percentage of participants who at 2 years from the start of treatment remained free from documented disease progression, relapse, or death. Failure status was based on tumor evaluation performed on Month 28. Participants who did not have a tumor evaluation at Month 28 were counted as failures.

    Time frame: Month 28

Secondary outcomes

  1. Percentage of Participants Achieving a Best Overall Response of CR, CRu, or PR by Study Phase

    CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.

    Time frame: Baseline, Months 4, 7 (Induction Phase), 11, 16 (Maintenance Phase),22, 28, 34, and 40(Follow-Up Phase)

  2. Percentage of Participants Achieving a Response by Response Type and Study Phase

    CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.

    Time frame: Baseline, Months 4, 7, 11, 16, 22, 28, 34, and 40

  3. Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death

    FFS data were analyzed using Kaplan-Meier survival analysis. FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or dropped out due to adverse events (AE) were censored at their last assessment date. The reported data refer to values up to 40 months.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  4. FFS - Percentage of Participants With an Event

    FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or who dropped out due to AEs were censored at their last assessment date.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  5. FFS - Time to Event

    FFS was measured from the date of treatment start to the date of documented disease progression, relapse or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent or dropped out due to AEs were censored at their last assessment date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  6. Overall Survival (OS) - Percentage of Participants Estimated to be Alive

    OS data were analyzed using Kaplan-Meier survival analysis. OS was defined as the time from first dosage of study drug to the date of death from any cause. Reported data refer to values up to 40 months.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  7. OS - Percentage of Participants With an Event

    OS was defined as the time from first dosage of study drug to the date of death from any cause.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.

  8. OS - Time to Event

    Overall survival was defined as the time from first dosage of study drug to the date of death from any cause.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.

  9. Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free

    DFS data were analyzed using Kaplan-Meier survival analysis. DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of CR to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored as of the death date. The reported data refer to values up to 40 months.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  10. DFS - Percentage of Participants With an Event

    DFS was defined for all patients who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.

  11. DFS - Time to Event

    DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.

  12. Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free

    PFS data were analyzed using Kaplan-Meier survival analysis. PFS was defined as the time from treatment start to the date of documented disease progression. Reported data refer to values up to 40 months.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  13. PFS - Percentage of Participants With an Event

    Progression-free survival was defined as the time from the date of treatment start to the date of documented disease progression.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  14. PFS - Time to Event

    Progression-free survival was defined as the time from treatment start to the date of documented disease progression. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  15. Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response

    DR data were analyzed using Kaplan-Meier survival analysis. DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  16. DR - Percentage of Participants With an Event

    DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

  17. DR - Time to Event

    DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

    Time frame: Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40

07

Results

Posted Aug 21, 2014

Participant flow

Induction Phase (Months 1 to 7 of Study)
Participant flow — Induction Phase (Months 1 to 7 of Study)
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started47
Completed44
Not completed3
Withdrew: Adverse event2
Withdrew: Withdrawal by subject1
Maintenance Phase (Months 8-16 of Study)
Participant flow — Maintenance Phase (Months 8-16 of Study)
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started44
Completed41
Not completed3
Withdrew: Adverse event2
Withdrew: Clinical relapse1
Follow-up (Months 17-40 of Study)
Participant flow — Follow-up (Months 17-40 of Study)
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started41
Completed37
Not completed4
Withdrew: Adverse event1
Withdrew: Protocol violation1
Withdrew: Disease progression2

Outcome measures

PrimaryPercentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date

Percentage of participants who at 2 years from the start of treatment remained free from documented disease progression, relapse, or death. Failure status was based on tumor evaluation performed on Month 28. Participants who did not have a tumor evaluation at Month 28 were counted as failures.

Time frame:
Month 28
Reported as:
Number · percentage of participants
Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants Remaining Failure-Free After 2 Years From Treatment Start Date73.9 (61.22 to 86.60)
Statistical analysis
  • Rituximab + Fludarabine + Cyclophosphamide · t-test, 2 sided · p = <0.0001
SecondaryPercentage of Participants Achieving a Best Overall Response of CR, CRu, or PR by Study Phase

CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.

Time frame:
Baseline, Months 4, 7 (Induction Phase), 11, 16 (Maintenance Phase),22, 28, 34, and 40(Follow-Up Phase)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Best Overall Response of CR, CRu, or PR by Study Phase
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Induction Phase95.7 (89.76 to 100.00)
Maintenance Phase80.4 (68.97 to 91.90)
SecondaryPercentage of Participants Achieving a Response by Response Type and Study Phase

CR: complete disappearance of all symptoms/objective signs of disease (enlarged lymph nodes, hepatomegaly, splenomegaly) for at least 3 months following definitive re-evaluation at end of therapy. For initial bone marrow involvement, clearance of bone marrow documented by biopsy, normalization of blood counts with granulocytes greater than (\>)1,500 per microliter (/µL), hemoglobin \>12 grams per deciliter (g/dL), platelets \>100,000/µL. CRu: disappearance of all symptoms and nearly all measurable lesions, but persistence of some radiologic abnormalities with normalization of all biologic abnormalities; normalization of the performance status for at least 3 months after the definite evaluation of therapy. PR: at least 50 percent (%) reduction of measurable and evaluable lymphoma involvement for at least 4 weeks without occurrence of new manifestations, normalization of blood counts. Participants without evaluation at end of induction/maintenance phase were considered nonresponders.

Time frame:
Baseline, Months 4, 7, 11, 16, 22, 28, 34, and 40
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Response by Response Type and Study Phase
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
CR at end of induction phase41.3
CR at end of maintenance phase45.7
CR at final assessment45.7
CRu at end of induction phase21.7
CRu at end of maintenance phase15.2
CRu at final assessment19.6
PR at end of induction phase32.6
PR at end of maintenance phase19.6
PR at final assessment13.0
Relapse at end of induction phase0
Relapse at end of maintenance phase0
Relapse at final assessment2.2
Unknown at end of induction phase4.3
Unknown at end of maintenance phase19.6
Unknown at final assessment19.6
SecondaryFailure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death

FFS data were analyzed using Kaplan-Meier survival analysis. FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or dropped out due to adverse events (AE) were censored at their last assessment date. The reported data refer to values up to 40 months.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Failure-Free Survival (FFS), Percentage of Participants Estimated to be Free of Documented Disease Progression, Relapse, or Death90.12 (75.48 to 96.23)
SecondaryFFS - Percentage of Participants With an Event

FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent, or who dropped out due to AEs were censored at their last assessment date.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
FFS - Percentage of Participants With an Event
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
FFS - Percentage of Participants With an Event8.7
SecondaryFFS - Time to Event

FFS was measured from the date of treatment start to the date of documented disease progression, relapse or death from any cause. Responding participants, participants who were lost to follow up, who withdrew consent or dropped out due to AEs were censored at their last assessment date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Mean · months
FFS - Time to Event
monthsRituximab + Fludarabine + Cyclophosphamide
FFS - Time to Event39.14 ± 0.70
SecondaryOverall Survival (OS) - Percentage of Participants Estimated to be Alive

OS data were analyzed using Kaplan-Meier survival analysis. OS was defined as the time from first dosage of study drug to the date of death from any cause. Reported data refer to values up to 40 months.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
Overall Survival (OS) - Percentage of Participants Estimated to be Alive
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Overall Survival (OS) - Percentage of Participants Estimated to be Alive97.44 (83.16 to 99.64)
SecondaryOS - Percentage of Participants With an Event

OS was defined as the time from first dosage of study drug to the date of death from any cause.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Reported as:
Number · percentage of participants
OS - Percentage of Participants With an Event
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
OS - Percentage of Participants With an Event2.17
SecondaryOS - Time to Event

Overall survival was defined as the time from first dosage of study drug to the date of death from any cause.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Reported as:
Mean · months
OS - Time to Event
monthsRituximab + Fludarabine + Cyclophosphamide
OS - Time to Event38.6 ± NA
SecondaryDisease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free

DFS data were analyzed using Kaplan-Meier survival analysis. DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of CR to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored as of the death date. The reported data refer to values up to 40 months.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Disease-Free Survival (DFS) - Percentage of Participants Estimated to be Disease-Free87.70 (65.84 to 95.96)
SecondaryDFS - Percentage of Participants With an Event

DFS was defined for all patients who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Reported as:
Number · percentage of participants
DFS - Percentage of Participants With an Event
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
DFS - Percentage of Participants With an Event10.34
SecondaryDFS - Time to Event

DFS was defined for all participants who achieved a complete response (CR/CRu) at month 1 after the completion of treatment of the induction phase (month 7 of the study) and was measured from the time of complete response to the date of relapse. Participants without relapse were censored at their last assessment date. Participants who died due to tumour burden were considered in relapse. Participants who died due to any other causes were censored on the death date. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40.
Reported as:
Mean · months
DFS - Time to Event
monthsRituximab + Fludarabine + Cyclophosphamide
DFS - Time to Event32.51 ± 0.58
SecondaryProgression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free

PFS data were analyzed using Kaplan-Meier survival analysis. PFS was defined as the time from treatment start to the date of documented disease progression. Reported data refer to values up to 40 months.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Progression-free Survival (PFS) - Percentage of Participants Estimated to Be Progress Free90.12 (75.48 to 96.23)
SecondaryPFS - Percentage of Participants With an Event

Progression-free survival was defined as the time from the date of treatment start to the date of documented disease progression.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
PFS - Percentage of Participants With an Event
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
PFS - Percentage of Participants With an Event8.70
SecondaryPFS - Time to Event

Progression-free survival was defined as the time from treatment start to the date of documented disease progression. NOTE: The mean survival time and its standard error were underestimated because the largest observation was censored and the estimation was restricted to the largest event time.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Mean · months
PFS - Time to Event
monthsRituximab + Fludarabine + Cyclophosphamide
PFS - Time to Event39.14 ± 0.70
SecondaryDuration of Response (DR) - Percentage of Participants Expected to Maintain a Response

DR data were analyzed using Kaplan-Meier survival analysis. DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
Duration of Response (DR) - Percentage of Participants Expected to Maintain a Response90.07 (75.45 to 96.19)
SecondaryDR - Percentage of Participants With an Event

DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Number · percentage of participants
DR - Percentage of Participants With an Event
percentage of participantsRituximab + Fludarabine + Cyclophosphamide
DR - Percentage of Participants With an Event9.09
SecondaryDR - Time to Event

DR was defined for all participants who achieved a response (CR, CRu and PR) at month 1 after the completion of treatment of the induction phase (Month 7 of the study) and was measured from the time of response until the date of progression or relapse. Participants without relapse or progression were censored at their last assessment date. Participants who died due to tumour were considered in progression. Participants who died for any other cause were censored to the death date.

Time frame:
Baseline, Months 1-8, 10-12, 14, 16, 22, 28, 34 and 40
Reported as:
Mean · months
DR - Time to Event
monthsRituximab + Fludarabine + Cyclophosphamide
DR - Time to Event32.19 ± 0.72

Adverse events

Collected over Treatment-emergent adverse events (AEs) were reported throughout the study (up to 40 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Fludarabine + Cyclophosphamide—16/47 (34%)47/47 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventRituximab + Fludarabine + Cyclophosphamide
PneumoniaInfections and infestations3/47
NeutropeniaBlood and lymphatic system disorders2/47
Febrile neutropeniaBlood and lymphatic system disorders1/47
Mitral valve incompetenceCardiac disorders1/47
Renal dysplasiaCongenital, familial and genetic disorders1/47
PyrexiaGeneral disorders1/47
CholecystitisHepatobiliary disorders1/47
BronchopneumoniaInfections and infestations1/47
Staphylococcal infectionInfections and infestations1/47
ArthralgiaMusculoskeletal and connective tissue disorders1/47
Most frequent other events
Showing 10 of 118
Most frequent other events
EventRituximab + Fludarabine + Cyclophosphamide
NeutropeniaBlood and lymphatic system disorders29/47
PyrexiaGeneral disorders23/47
CoughRespiratory, thoracic and mediastinal disorders21/47
NauseaGastrointestinal disorders20/47
LeukopeniaBlood and lymphatic system disorders18/47
AstheniaGeneral disorders16/47
StomatitisGastrointestinal disorders10/47
AnaemiaBlood and lymphatic system disorders8/47
Herpes zosterInfections and infestations8/47
BronchitisInfections and infestations6/47

Baseline characteristics

Intent-to-Treat (ITT) population: all enrolled participants who completed at least 2 cycles of treatment.

Age, Continuous
Age, Continuous(years)Rituximab + Fludarabine + Cyclophosphamide
Mean57.3 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Fludarabine + Cyclophosphamide
Female18
Male28
08

Study locations

15 sites
  • Ospedale Civile Dello Spirito Santo; Divisione Di Ematologia
    Pescara, Abruzzo 65100, Italy
  • Ospedale Civile; Divisione Di Oncologia
    Pescara, Abruzzo 65124, Italy
  • Ospedale Oncologico Regionale; U.O. Oncologia Medica Ed Ematologia
    Rionero in Vulture, Basilicata 85028, Italy
  • Ospedale Riuniti; Divisione Di Ematologia
    Reggio Calabria, Calabria 89100, Italy
  • A.O.U. Policlinico di Modena-Dipartimento di Medicina Diagnostica, Clinica e di Sanità pubblica
    Modena, Emilia-Romagna 41100, Italy
  • Az. Osp. Arcispedale S. Maria Nuova; U.O. Di Ematologia
    Reggio Emilia, Emilia-Romagna 42100, Italy
  • Universita' Degli Studi La Sapienza-Ist.Di Ematologia;Dip. Biotecnologie Cel CELLULARI ED EMATOLOGIA
    Roma, Lazio 00161, Italy
  • A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia
    Brescia, Lombardia 25123, Italy
  • Ospedale Maggiore Di Milano; U.O. Ematologia I - Padiglione Marcora
    Milano, Lombardia 20122, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia
    Alessandria, Piemonte 15121, Italy
  • Az. Osp. S. Croce Ospedale Generale; Sezione Di Ematologia
    Cuneo, Piemonte 12100, Italy
  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino; Ematologia 1
    Torino, Piemonte 10126, Italy
  • Az. Osp. Papardo; Struttura Complessa Di Ematologia
    Messina, Sicilia 98165, Italy
  • Az. Osp. Di Careggi; Divisione Di Ematologia
    Firenze, Toscana 50135, Italy
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2005 to primary completion in Sep 2010, 62 months.

Results were first posted in Aug 2014, 3 years 10 months after primary completion.

Of 50 industry-sponsored phase 2 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 77. This study's 62 months is above that.

Counting every sponsor, half of 220 studies reached it within 65 months; a quarter within 41 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 30, 2010
StartActual
Jul 20, 2005
Primary completionActual
Sep 24, 2010
CompletionActual
Sep 24, 2010
Results first posted
Aug 21, 2014
Last update
Aug 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01153971
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 30, 2010
Start date
Jul 20, 2005
Primary completion
Sep 24, 2010
Completion
Sep 24, 2010
Results posted
Aug 21, 2014
Last update
Aug 1, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion